Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lycera closes first tranche of $36mm Series A round; adds on

Executive Summary

Lycera (small-molecule immunomodulators) received $10mm of a planned $36mm Series A financing. InterWest Partners, ARCH Venture Partners, and Clarus Ventures co-led (and take seats on Lycera's board), and seed investor EDF Ventures also participated. The remainder of the funds will be available to the company in two additional tranches as specific development milestones are achieved.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies